
Tara O’Donohue, MD, MS
Pediatric Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Early Phase Clinical Trials
- Precision Oncology
- Developmental Therapeutics
Request an Appointment
About Me
- Assistant Attending Pediatrician
I am a pediatric oncologist on the MSK Kids team who specializes in early-phase clinical trials evaluating promising new treatments for pediatric cancers. I am a member of the Sarcoma Service at Memorial Sloan Kettering Cancer Center (MSK), where I care for pediatric and young adult patients with soft-tissue and bone sarcomas, as well as rare pediatric solid tumors.
Read more
At MSK, I also help lead the Pediatric Translational Medicine Program’s (PTMP) clinical service. This program allows us to closely study and sequence tumors for mutations and other molecular changes in every child and young adult with cancer at MSK. The information that we learn about a patient’s tumor may provide valuable clues that can be used to select the most appropriate therapies for each patient. It also allows us to start new research projects and develop potentially lifesaving drugs.
Many of the early-phase clinical trials that we conduct through the PTMP are focused on getting the “right drug” to the “right patient.” Historically, we would treat all patients with a certain type of cancer the same way; however, thanks to recent advances in genomic profiling and increased accessibility of these technologies, we are starting to understand what makes each tumor different. This means that we can tailor treatments to the unique biology of a patient’s cancer.
It is not only exciting due to the rapid advances in scientific discovery in our field, but also because these findings may have broad-reaching impact, improving patient outcomes on a large scale.
Patients and families who are seeking early-phase clinical trials have often already gone through so much, and I acknowledge that finding the right trial can be a long and strenuous process. Therefore, when I meet a patient and their family for the first time, I try to learn as much as I can about them, as each child and family have unique experiences, values, and goals. This way, I am best positioned to support each patient and family based on their specific situation and preferences while considering the most up to date scientific evidence when creating a treatment plan with our dedicated team of experts at MSK Kids (physicians, advance practice providers, nurses, pharmacists, social workers, researchers, and more).
I initially became interested in pediatric cancer care and research when a family member of mine was being treated at MSK. At the time, I decided to volunteer with Child Life Services, and I was completely in awe of the pediatric patients’ resilience and their families’ strength and grace. I am humbled to be able to provide care for children and young adults affected by cancer, and I am honored to do so alongside an incredibly dedicated team at MSK Kids who work tirelessly to inch closer to finding a cure for pediatric cancer.
A pediatric oncologist is a doctor with special training in cancer in children and adolescents.
My Specialties
- Early Phase Clinical Trials
- Precision Oncology
- Developmental Therapeutics
- Rare Pediatric Tumors
- Relapsed and Refractory Tumors in Pediatric and Young Adult Patients
- Pediatric Sarcomas
Education
- MD, Rutgers Robert Wood Johnson Medical School
- MS, Weill Cornell Medicine Clinical & Translational Science Center
Residencies
- Pediatrics - NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Awards and Honors
- Research Fellow, Margaux’s Miracle Foundation (2020)
- Medical Oncology Fellow, The Kristen Ann Carr Fund (2019)
- Betty Neuwirth Lee Fellow (2018)
Fellowships
- Pediatric Hematology/Oncology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medicine
Board Certifications
- Pediatrics
- Pediatric Hematology/Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

New Patients
Current Patients
Contact and Location
Dr. O’Donohue sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. O’Donohue
- A Phase I/II Study of Repotrectinib in Children and Young Adults with Advanced or Metastatic Cancers Containing ALK, ROS1, or NTRK1-3 Alterations
- A Phase I/II Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Advanced Solid Tumors
- Clinical Trials Co-Investigated by Dr. O’Donohue
- A Phase 1/2 Study of CBL0137 to Treat Advanced Solid Tumors in Children and Young Adults
- A Phase I Study of Idasanutlin Alone or with Chemotherapy in Pediatric and Young Adult Patients with Recurrent or Persistent Solid Tumors
Read more
- A Phase I/II Study of Alectinib in Children and Adolescents with Solid Tumors or Central Nervous System Tumors Containing a Change in the ALK Gene
- A Phase I/II Study of Neratinib in Children and Adolescents with Recurrent or Persistent Cancer
- A Phase II Study of Hu3F8 plus GM-CSF to Prevent Osteosarcoma Recurrence

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Tara O’Donohue discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].